Ontologies Classes Object Properties Data Properties Annotation Properties Individuals Datatypes Clouds

Class: Stage_3A_NSCLC

Annotations (1)

rdfs:comment "The initial treatment for stage IIIA NSCLC may include some combination of radiation therapy, chemotherapy (chemo), and/or surgery. For this reason, planning treatment for stage IIIA NSCLC often requires input from a medical oncologist, radiation oncologist, and a thoracic surgeon. Your treatment options depend on the size of the tumor, where it is in your lung, which lymph nodes it has spread to, your overall health, and how well you are tolerating treatment. For patients who can tolerate it, treatment usually starts with chemo, often combined with radiation therapy (also called chemoradiation). Surgery may be an option after this if the doctor thinks any remaining cancer can be removed and the patient is healthy enough. For certain stage IIIA cancers, another treatment option is immunotherapy with nivolumab along with chemotherapy first and then surgery. Additional therapy after surgery might be needed depending on what is found at the time of surgery. In some cases, surgery may be an option as the first treatment. This is often followed by adjuvant chemo, which in turn might be followed by adjuvant immunotherapy for up to a year in some cases. Adjuvant radiation therapy might also be an option if it hasn't been given before. For people whose cancer cells have certain mutations in the EGFR gene, adjuvant treatment with the targeted drug osimertinib might be an option at some point as well. For people who are not healthy enough for surgery, radiation therapy, which may be combined with chemo, is often used. If surgery, radiation, and chemoradiation are not likely to be good treatment options, an immunotherapy drug such as pembrolizumab (Keytruda) or cemiplimab (Libtayo) may be considered as the first treatment."

Superclasses (1)

Non-Small_Cell_LC

Disjoints (690)

```
"\'Abraxane_(Paclitaxel_Albumin-stabilized_Nanoparticle_Formulation)_\", '\'Afinitor_(Everolimus)\",
'\'Afinitor_Disperz_(Everolimus)_\'', '\'Alecensa_(Alectinib)_\'', '\'Alimta_(Pemetrexed_Disodium)_\'',
'\'Alunbrig_(Brigatinib)_\", '\'Alymsys_(Bevacizumab)_\", '\'Avastin_(Bevacizumab)_\",
'\'Cyramza_(Ramucirumab)_\", '\'Enhertu_(Fam-Trastuzumab_Deruxtecan-nxki)_\",
\\'\'Etopophos_(Etoposide_Phosphate)_\'', \\'Exkivity_(Mobocertinib_Succinate)_\'', \\'Gavreto_(Pralsetinib)_\'', \\'Gemzar_(Gemcitabine_Hydrochloride)_\'', \\'Gilotrif_(Afatinib_Dimaleate)_\'', \\'Hycamtin_(Topotecan_Hydrochloride)_\'', \\'Imfinzi_(Durvalumab)_\'', \\'Imjudo_(Tremelimumab-actl)_\'', \\'Infugem_(Gemcitabine_Hydrochloride)_\'', \\'Iressa_(Gefitinib)_\\'', \\'Keytruda_(Pembrolizumab)_\\'', \\'Infugem_(Gemcitabine_Hydrochloride)_\'', \\'Iressa_(Gemcitabine_Hydrochloride)_\\'', \\''', \\''', \\''', \\''', \\''', \\''', \\''', \\'''
'\'Krazati_(Adagrasib)_\'', '\'Libtayo_(Cemiplimab-rwlc)_\'', '\'Lorbrena_(Lorlatinib)_\'', '\'Lumakras_(Sotorasib)_\'', '\'Mekinist_(Trametinib_Dimethyl_Sulfoxide)_\'', '\'Mvasi_(Bevacizumab)_\'',
'\'Opdivo_(Nivolumab)_\'', '\'Portrazza_(Necitumumab)_\'', '\'Retevmo_(Selpercatinib)_\'',
'\'Rozlytrek_(Entrectinib)_\'', '\'Rybrevant_(Amivantamab-vmjw)_\'',
'<u>\'Tabrecta (Capmatinib Hydrochloride) \''</u>, '\'Tafinlar_(Dabrafenib_Mesylate)_\'',
4A_NSCLC, 4B_NSCLC, Adagrasib_, Adherence_Based_on_Socioeconomics_LC, Adherence_Factors_LC,
Adverse_Reactions_ABRAX, Adverse_Reactions_ADAGR, Adverse_Reactions_AFATI, Adverse_Reactions_AFINI,
Adverse Reactions AFINIT, Adverse Reactions ALECE, Adverse Reactions ALIMT, Adverse Reactions ALUNB,
Adverse_Reactions_ALYMS, Adverse_Reactions_AVAST, Adverse_Reactions_AVAST,
Adverse_Reactions_BRIGA, Adverse_Reactions_CAPMA, Adverse_Reactions_CEMIP, Adverse_Reactions_CYRAM,
Adverse_Reactions_DOXOR, Adverse_Reactions_DURVA, Adverse_Reactions_ENHER,
Adverse_Reactions_ENTRE, Adverse_Reactions_ERLOT, Adverse_Reactions_ETOP, Adverse_Reactions_ETOPO,
Adverse_Reactions_EXKIV, Adverse_Reactions_GAVRE, Adverse_Reactions_GEFIT, Adverse_Reactions_GEMZA,
Adverse_Reactions_GILOT, Adverse_Reactions_HYCAM, Adverse_Reactions_IMFIN, Adverse_Reactions_IMJUD,
Adverse_Reactions_INFUG, Adverse_Reactions_IRESS, Adverse_Reactions_KEYTR, Adverse_Reactions_KRAZA,
Adverse Reactions LIBTA, Adverse Reactions LORBR, Adverse Reactions LUMAK, Adverse Reactions LURB,
Adverse Reactions MEKIN, Adverse Reactions METH, Adverse Reactions MVASI, Adverse Reactions OPDIV,
Adverse Reactions PORTR, Adverse Reactions RAMUC, Adverse Reactions RETEV, Adverse Reactions ROZLY,
Adverse Reactions RYBRE, Adverse Reactions SELPE, Adverse Reactions SOTOR, Adverse Reactions TABRE,
Adverse Reactions TAFIN, Adverse Reactions TAGRIS, Adverse Reactions TAXOT, Adverse Reactions TECEN,
Adverse Reactions TEPME, Adverse Reactions TOPO, Adverse Reactions TRAME, Adverse Reactions TREME,
```

Adverse_Reactions_TREXA, Adverse_Reactions_VINOR, Adverse_Reactions_VIZIM, Adverse_Reactions_XALKO, Adverse_Reactions_YERVO, Adverse_Reactions_ZIRAB, Adverse_Reactions_ZYKAD, Afatinib_Dimaleate_, Age, Air_Pollution, Amivantamab-vmjw_, Atezolizumab_, Behavioral_Factors_LC, Beta_Carotene_Supplements_LC, Bio_Sensors_LC, Biological_Effects_LC, Breathalyzer_LC, Breathing_LC, Brigatinib_, Capmatinib_Hydrochloride_, Causes_and_Risks_LC, Cemiplimab-rwlc_, Chemical_Sensors_LC, Choosing_Quality_of_Life_-_Reasons_People_Forego_Treatment, Choosing_Survival_-_Deciding_to_Undergo_Treatment, Complications_LC, Contraindications_ABRAX, Contraindications_ADAGR, Contraindications_AFATI, Contraindications_AFINI, Contraindications_AFINIT, Contraindications_ALECE, Contraindications ALIMT, Contraindications ALUNB, Contraindications ALYMS, Contraindications AMIVA, Contraindications ATEZO, Contraindications AVAST, Contraindications BRIGA, Contraindications CAPMA, Contraindications_CEMIP, Contraindications_CYRAM, Contraindications_DOXOR, Contraindications_DURVA, Contraindications_ENHER, Contraindications_ENTRE, Contraindications_ERLOT, Contraindications_ETOP, Contraindications_ETOPO, Contraindications_EXKIV, Contraindications_GAVRE, Contraindications_GEFIT, Contraindications_GEMZA, Contraindications_GILOT, Contraindications_HYCAM, Contraindications_IMFIN, Contraindications_IMJUD, Contraindications_INFUG, Contraindications_IRESS, Contraindications_KEYTR, Contraindications_KRAZA, Contraindications_LIBTA, Contraindications_LORBR, Contraindications_LUMAK, Contraindications_LURB, Contraindications_MEKIN, Contraindications_METH, Contraindications_MVASI, Contraindications_OPDIV, Contraindications_PORTR, Contraindications_RAMUC, Contraindications_RETEV, Contraindications_ROZLY, Contraindications_RYBRE, Contraindications_SELPE, Contraindications_SOTOR, Contraindications_TABRE, Contraindications_TAFIN, Contraindications_TAGRIS, Contraindications_TAXOT, Contraindications_TECEN, Contraindications_TEPME, Contraindications_TOPO, Contraindications_TRAME, Contraindications_TREME, Contraindications_TREXA, Contraindications_VINOR, Contraindications_VIZIM, Contraindications_XALKO, Contraindications_YERVO, Contraindications_ZIRAB, Contraindications_ZYKAD, Cultural_Beliefs_and_Perceptions, Cultural_LC, Degrees_of_Smoking_LC, Demographic_Factors_LC, Diet_LC, Disparities in Incidence, Dosage and Administration ABRAX, Dosage and Administration ADAGR, Dosage_and_Administration_AFATI, Dosage_and_Administration_AFINI, Dosage_and_Administration_AFINIT, Dosage_and_Administration_ALECE, Dosage_and_Administration_ALIMT, Dosage_and_Administration_ALUNB, Dosage_and_Administration_ALYMS, Dosage_and_Administration_AMIVA, Dosage_and_Administration_ATEZO, Dosage_and_Administration_AVAST, Dosage_and_Administration_BRIGA, Dosage_and_Administration_CAPMA, Dosage_and_Administration_CEMIP, Dosage_and_Administration_CYRAM, Dosage_and_Administration_DOXOR, Dosage_and_Administration_DURVA, Dosage_and_Administration_ENHER, Dosage_and_Administration_ENTRE, Dosage and Administration ERLOT, Dosage and Administration ETOP, Dosage and Administration ETOPO, Dosage_and_Administration_EXKIV, Dosage_and_Administration_GAVRE, Dosage_and_Administration_GEFIT, Dosage_and_Administration_GEMZA, Dosage_and_Administration_GILOT, Dosage_and_Administration_HYCAM, Dosage and Administration IMFIN, Dosage and Administration IMJUD, Dosage and Administration INFUG, Dosage_and_Administration_IRESS, Dosage_and_Administration_KEYTR, Dosage_and_Administration_KRAZA, Dosage_and_Administration_LIBTA, Dosage_and_Administration_LORBR, Dosage_and_Administration_LUMAK, Dosage_and_Administration_LURB, Dosage_and_Administration_MEKIN, Dosage_and_Administration_METH, Dosage and Administration MVASI, Dosage and Administration OPDIV, Dosage and Administration PORTR, Dosage_and_Administration_RAMUC, Dosage_and_Administration_RETEV, Dosage_and_Administration_ROZLY, Dosage_and_Administration_RYBRE, Dosage_and_Administration_SELPE, Dosage_and_Administration_SOTOR, Dosage_and_Administration_TABRE, Dosage_and_Administration_TAFIN, Dosage_and_Administration_TAGRIS, Dosage_and_Administration_TAXOT, Dosage_and_Administration_TECEN, Dosage_and_Administration_TEPME, Dosage and Administration TOPO, Dosage and Administration TRAME, Dosage and Administration TREME, Dosage and Administration TREXA, Dosage and Administration VINOR, Dosage and Administration VIZIM, Dosage and Administration XALKO, Dosage and Administration YERVO, Dosage and Administration ZIRAB, Dosage and Administration ZYKAD, Dosage Forms and Strengths ABRAX, Dosage Forms and Strengths ADAGR, Dosage Forms and Strengths AFATI, Dosage Forms and Strengths AFINI, Dosage Forms and Strengths AFINIT, Dosage Forms and Strengths ALECE, Dosage Forms and Strengths ALIMT, Dosage Forms and Strengths ALUNB, Dosage Forms and Strengths ALYMS, Dosage_Forms_and_Strengths_AMIVA, Dosage_Forms_and_Strengths_ATEZO, Dosage_Forms_and_Strengths_AVAST, Dosage_Forms_and_Strengths_BRIGA, Dosage Forms and Strengths CAPMA, Dosage Forms and Strengths CEMIP, Dosage Forms and Strengths CYRAM, Dosage Forms and Strengths DOXOR, Dosage_Forms_and_Strengths_DURVA, Dosage_Forms_and_Strengths_ENHER, Dosage Forms and Strengths ENTRE, Dosage Forms and Strengths ERLOT, Dosage Forms and Strengths ETOP, Dosage Forms and Strengths ETOPO, Dosage_Forms_and_Strengths_EXKIV, Dosage_Forms_and_Strengths_GAVRE, Dosage_Forms_and_Strengths_GEFIT, Dosage_Forms_and_Strengths_GEMZA, Dosage_Forms_and_Strengths_GILOT, Dosage_Forms_and_Strengths_HYCAM, Dosage Forms and Strengths IMFIN, Dosage Forms and Strengths IMJUD, Dosage_Forms_and_Strengths_INFUG, Dosage_Forms_and_Strengths_IRESS, Dosage_Forms_and_Strengths_KEYTR, Dosage_Forms_and_Strengths_KRAZA, Dosage_Forms_and_Strengths_LIBTA, Dosage_Forms_and_Strengths_LORBR,

```
Dosage_Forms_and_Strengths_LUMAK, Dosage_Forms_and_Strengths_LURB,
Dosage_Forms_and_Strengths_MEKIN, Dosage_Forms_and_Strengths_METH,
Dosage_Forms_and_Strengths_MVASI, Dosage_Forms_and_Strengths_OPDIV,
Dosage_Forms_and_Strengths_PORTR, Dosage_Forms_and_Strengths_RAMUC,
Dosage_Forms_and_Strengths_RETEV, Dosage_Forms_and_Strengths_ROZLY,
Dosage_Forms_and_Strengths_RYBRE, Dosage_Forms_and_Strengths_SELPE,
Dosage_Forms_and_Strengths_SOTOR, Dosage_Forms_and_Strengths_TABRE,
Dosage_Forms_and_Strengths_TAFIN, Dosage_Forms_and_Strengths_TAGRIS,
Dosage Forms and Strengths TAXOT, Dosage Forms and Strengths TECEN,
Dosage_Forms_and_Strengths_TEPME, Dosage_Forms_and_Strengths_TOPO,
Dosage_Forms_and_Strengths_TRAME, Dosage_Forms_and_Strengths_TREME,
Dosage_Forms_and_Strengths_TREXA, Dosage_Forms_and_Strengths_VINOR,
Dosage_Forms_and_Strengths_VIZIM, Dosage_Forms_and_Strengths_XALKO,
Dosage_Forms_and_Strengths_YERVO, Dosage_Forms_and_Strengths_ZIRAB,
Dosage_Forms_and_Strengths_ZYKAD, Doxorubicin_Hydrochloride_, Drug_Interactions_ABRAX,
Drug_Interactions_ADAGR, Drug_Interactions_AFATI, Drug_Interactions_AFINI, Drug_Interactions_AFINIT,
Drug_Interactions_ALECE, Drug_Interactions_ALIMT, Drug_Interactions_ALUNB, Drug_Interactions_ALYMS,
Drug_Interactions_AMIVA, Drug_Interactions_ATEZO, Drug_Interactions_AVAST, Drug_Interactions_BRIGA,
Drug_Interactions_CAPMA, Drug_Interactions_CEMIP, Drug_Interactions_CYRAM, Drug_Interactions_DOXOR,
Drug_Interactions_DURVA, Drug_Interactions_ENHER, Drug_Interactions_ENTRE, Drug_Interactions_ERLOT,
Drug_Interactions_ETOP, Drug_Interactions_ETOPO, Drug_Interactions_EXKIV, Drug_Interactions_GAVRE,
Drug_Interactions_GEFIT, Drug_Interactions_GEMZA, Drug_Interactions_GILOT, Drug_Interactions_HYCAM,
Drug_Interactions_IMFIN, Drug_Interactions_IMJUD, Drug_Interactions_INFUG, Drug_Interactions_IRESS,
Drug_Interactions_KEYTR, Drug_Interactions_KRAZA, Drug_Interactions_LIBTA, Drug_Interactions_LORBR,
Drug Interactions LUMAK, Drug Interactions LURB, Drug Interactions MEKIN, Drug Interactions METH,
Drug_Interactions_MVASI, Drug_Interactions_OPDIV, Drug_Interactions_PORTR, Drug_Interactions_RAMUC,
Drug_Interactions_RETEV, Drug_Interactions_ROZLY, Drug_Interactions_RYBRE, Drug_Interactions_SELPE,
Drug_Interactions_SOTOR, Drug_Interactions_TABRE, Drug_Interactions_TAFIN, Drug_Interactions_TAGRIS,
Drug_Interactions_TAXOT, Drug_Interactions_TECEN, Drug_Interactions_TEPME, Drug_Interactions_TOPO,
Drug_Interactions_TRAME, Drug_Interactions_TREME, Drug_Interactions_TREXA, Drug_Interactions_VINOR,
Drug_Interactions_VIZIM, Drug_Interactions_XALKO, Drug_Interactions_YERVO, Drug_Interactions_ZIRAB,
Drug_Interactions_ZYKAD, Durvalumab_, E-Cigarettes_LC, Electronic_Sensors_LC, Emotions_LC,
End_of_Life_Decisions, Entrectinib_, Environmental_Factors_LC, Enzymatic_Sensors_LC,
Erlotinib_Hydrochloride_, Etoposide_, Exercise_LC, Extensive_Stage_SCLC, Family_History_LC, Gefitinib_,
Genomic Sequencing LC, Geographical Location, Habits LC, HIV Infection LC, Immunosensors LC,
Increased_Susceptibility_LC, Indications_and_Usage_ABRAX, Indications_and_Usage_ADAGR,
Indications_and_Usage_AFATI, Indications_and_Usage_AFINI, Indications_and_Usage_AFINIT,
Indications_and_Usage_ALECE, Indications_and_Usage_ALIMT, Indications_and_Usage_ALUNB,
Indications and Usage ALYMS, Indications and Usage AMIVA, Indications and Usage ATEZO,
Indications_and_Usage_AVAST, Indications_and_Usage_BRIGA, Indications_and_Usage_CAPMA,
Indications_and_Usage_CEMIP, Indications_and_Usage_CYRAM, Indications_and_Usage_DOXOR,
Indications_and_Usage_DURVA, Indications_and_Usage_ENHER, Indications_and_Usage_ENTRE,
Indications_and_Usage_ERLOT, Indications_and_Usage_ETOP, Indications_and_Usage_ETOPO,
Indications_and_Usage_EXKIV, Indications_and_Usage_GAVRE, Indications_and_Usage_GEFIT,
Indications and Usage GEMZA, Indications and Usage GILOT, Indications and Usage HYCAM,
Indications and Usage IMFIN, Indications and Usage IMJUD, Indications and Usage INFUG,
Indications and Usage IRESS, Indications and Usage KEYTR, Indications and Usage KRAZA,
Indications and Usage LIBTA, Indications and Usage LORBR, Indications and Usage LUMAK,
Indications and Usage LURB, Indications and Usage MEKIN, Indications and Usage METH,
Indications and Usage MVASI, Indications and Usage OPDIV, Indications and Usage PORTR,
Indications and Usage RAMUC, Indications and Usage RETEV, Indications and Usage ROZLY,
Indications_and_Usage_RYBRE, Indications_and_Usage_SELPE, Indications_and_Usage_SOTOR,
Indications_and_Usage_TABRE, Indications_and_Usage_TAFIN, Indications_and_Usage_TAGRIS,
Indications and Usage TAXOT, Indications and Usage TECEN, Indications and Usage TEPME,
Indications_and_Usage_TOPO, Indications_and_Usage_TRAME, Indications_and_Usage_TREME,
Indications_and_Usage_TREXA, Indications_and_Usage_VINOR, Indications_and_Usage_VIZIM,
Indications_and_Usage_XALKO, Indications_and_Usage_YERVO, Indications_and_Usage_ZIRAB,
Indications_and_Usage_ZYKAD, Limited_Stage_SCLC, Living_with_LC_LC, Location_LC, Lurbinectedin_,
Marijuna_Smoking_LC, Medications_LC, Methotrexate_Sodium_, Never-Smokers_LC, Non-
Small_Cell_LC_NSCLC, Non-Small_Cell_Lung_Cancer, Non-Small_Cell_Medication_LC_, Non-Smokers_LC, Non-Small_Cell_Lung_Cancer, Non-Small_Cell_Medication_LC_, Non-Smokers_LC, Non-Small_Cell_Lung_Cancer, Non-Small_Cell_Medication_LC_, Non-Smokers_LC_, Non-Smokers_LC_, Non-Small_Cell_Lung_Cancer, Non-Small_Cell_Medication_LC_, Non-Smokers_LC_, Non-Small_Cell_Medication_LC_, Non-Smokers_LC_, Non-Smokers_LC_, Non-Small_Cell_Medication_LC_, Non-Smokers_LC_, Non-Smokers_
Smokers_NSCLC, Non-Smokers_SCLC, Nutrition_LC, Occupational_Exposure,
Physical_Activity_For_Mitigation_of__LC, Physical_Activity_For_Prevention_Of_LC, Preventative_habits_LC,
Quitting/Not_Smoking_LC, Racial/Ethnic, Radiation_Exposure_LC, Ramucirumab_, Recurring_LC_NSCLC,
Recurring_LC_SCLC, Rural_LC, Second-hand_Smoke_LC, Secondhand_Smoke_LC, Selpercatinib_,
Sensor_Factors_LC, Size_of_the_community_LC, Sleep_LC, Small_Cell_LC, Small_Cell_LC_SCLC,
```

Small_Cell_Lung_Cancer, Small_Cell_Medication_LC_, Smoke_LC, Smokers_LC, Smokers_NSCLC, Smokers_SCLC, Smoking_LC, Smoking_Marijuana_LC, Smoking_Other_Drugs_LC, Smoking_Tobacco_LC, Socioeconomics_LC, Sotorasib_, Stage_0_NSCLC, Stage_1_NSCLC, Stage_1_SCLC, Stage_2_NSCLC, Stage_3A_NSCLC, Stage_3B_NSCLC, Stage_4_NSCLC, Support_Groups_LC, Symptoms_and_Tests_LC, Symptoms_NSC, Symptoms_SC, Tests_NSC, Tests_SC, Tobacco_Smoking, Tobacco_Smoking_LC, Topotecan_Hydrochloride_, Tramentinib_Dimethyl_Sulfoxide, Treatment_Regimens_LC, Tremelimumab-actl_, Urban_LC, Use_in_Specific_Populations_ABRAX, Use_in_Specific_Populations_ADAGR, Use_in_Specific_Populations_AFATI, Use_in_Specific_Populations_AFINI, Use_in_Specific_Populations_AFINIT, Use in Specific Populations ALECE, Use in Specific Populations ALIMT, Use in Specific Populations ALUNB, Use in Specific Populations ALYMS, Use in Specific Populations AMIVA, Use in Specific Populations ATEZO, Use_in_Specific_Populations_AVAST, Use_in_Specific_Populations_BRIGA, Use_in_Specific_Populations_CAPMA, Use_in_Specific_Populations_CEMIP, Use_in_Specific_Populations_CYRAM, Use in Specific Populations DOXOR, Use in Specific Populations DURVA, Use_in_Specific_Populations_ENHER, Use_in_Specific_Populations_ENTRE, Use_in_Specific_Populations_ERLOT, Use_in_Specific_Populations_ETOP, Use_in_Specific_Populations_ETOPO, Use_in_Specific_Populations_EXKIV, Use_in_Specific_Populations_GAVRE, Use_in_Specific_Populations_GEFIT, Use_in_Specific_Populations_GEMZA, Use_in_Specific_Populations_GILOT, Use_in_Specific_Populations_HYCAM, Use_in_Specific Populations IMFIN, Use_in_Specific_Populations_INFUG, Use_in_Specific_Populations_INFUG, Use_in_Specific_Populations_IRESS, Use_in_Specific_Populations_KEYTR, Use_in_Specific_Populations_KRAZA, Use_in_Specific_Populations_LIBTA, Use_in_Specific_Populations_LORBR, Use_in_Specific_Populations_LUMAK, Use_in_Specific_Populations_LURB, Use_in_Specific_Populations_MEKIN, Use_in_Specific_Populations_METH, Use_in_Specific_Populations_MVASI, Use_in_Specific_Populations_OPDIV, Use_in_Specific_Populations_PORTR, Use_in_Specific_Populations_RAMUC, Use_in_Specific_Populations_RETEV, Use_in_Specific_Populations_ROZLY, Use_in_Specific_Populations_RYBRE, Use_in_Specific_Populations_SELPE, Use_in_Specific_Populations_SOTOR, Use_in_Specific_Populations_TABRE, Use in Specific Populations TAFIN, Use in Specific Populations TAGRIS, Use in Specific Populations TAXOT, Use_in_Specific_Populations_TECEN, Use_in_Specific_Populations_TEPME, Use_in_Specific_Populations_TOPO, Use_in_Specific_Populations_TRAME, Use_in_Specific_Populations_TREME, Use_in_Specific_Populations_TREXA, Use_in_Specific_Populations_VINOR, Use_in_Specific_Populations_VIZIM, Use_in_Specific_Populations_XALKO, Use_in_Specific_Populations_YERVO, Use_in_Specific_Populations_ZIRAB, Use_in_Specific_Populations_ZYKAD, Vinorelbine_Tartrate_, Warnings_and_Precautions_ABRAX, Warnings_and_Precautions_ADAGR, Warnings_and_Precautions_AFATI, Warnings_and_Precautions_AFINI, Warnings_and_Precautions_AFINIT, Warnings and Precautions ALECE, Warnings and Precautions ALIMT, Warnings and Precautions ALUNB, Warnings and Precautions ALYMS, Warnings and Precautions AMIVA, Warnings and Precautions ATEZO, Warnings and Precautions AVAST, Warnings and Precautions BRIGA, Warnings and Precautions CAPMA, Warnings and Precautions CEMIP, Warnings and Precautions CYRAM, Warnings and Precautions DOXOR, Warnings and Precautions DURVA, Warnings and Precautions ENHER, Warnings and Precautions ENTRE, Warnings_and_Precautions_ERLOT, Warnings_and_Precautions_ETOP, Warnings_and_Precautions_ETOPO, Warnings_and_Precautions_EXKIV, Warnings_and_Precautions_GAVRE, Warnings_and_Precautions_GEFIT, Warnings and Precautions GEMZA, Warnings and Precautions GILOT, Warnings and Precautions HYCAM, Warnings and Precautions IMFIN, Warnings and Precautions IMJUD, Warnings and Precautions INFUG, Warnings_and_Precautions_IRESS, Warnings_and_Precautions_KEYTR, Warnings_and_Precautions_KRAZA, Warnings_and_Precautions_LIBTA, Warnings_and_Precautions_LORBR, Warnings_and_Precautions_LUMAK, Warnings_and_Precautions_LURB, Warnings_and_Precautions_MEKIN, Warnings_and_Precautions_METH, Warnings and Precautions MVASI, Warnings and Precautions OPDIV, Warnings and Precautions PORTR, Warnings and Precautions RAMUC, Warnings and Precautions RETEV, Warnings and Precautions ROZLY, Warnings and Precautions RYBRE, Warnings and Precautions SELPE, Warnings and Precautions SOTOR, Warnings and Precautions TABRE, Warnings and Precautions TAFIN, Warnings and Precautions TAGRIS, Warnings and Precautions TAXOT, Warnings and Precautions TECEN, Warnings and Precautions TEPME, Warnings and Precautions TOPO, Warnings and Precautions TRAME, Warnings and Precautions TREME, Warnings and Precautions TREXA, Warnings and Precautions VINOR, Warnings and Precautions VIZIM, Warnings and Precautions XALKO, Warnings and Precautions YERVO, Warnings and Precautions ZIRAB, Warnings and Precautions ZYKAD

OWL HTML inside